Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases  

作　　者：Marwan S M Al-Nimer 

机构地区：[1]Department of Pharmacology,College of Medicine,University of Diyala,Baqubah 32001,Iraq

出　　处：《World Journal of Hepatology》2024年第9期1308-1311,共4页世界肝病学杂志（英文）

摘　　要：The albumin-bilirubin(ALBI)score is a useful prognostic marker that predicts mortality in patients suffering from terminal diseases.Recently,it has been reported that ALBI score is a predictor of non-malignant liver diseases.The cutoff point of the ALBI score that distinguishes hepatocellular carcinoma from non-malignant liver disease is still not identified.Therefore,the ALBI score is a sensi-tive rather than a specific predictor of the poor outcomes of liver diseases.There are many hematological indices and ratios that are utilized as prognostic biomarkers.Among these biomarkers are the neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio(PLR),and platelet-hemoglobin ratio(PHR),which are useful discriminating prognostic biomarkers for liver diseases,e.g.,hepato-cellular carcinoma,hepatitis,liver fibrosis,etc.There is evidence that PLR and PHR are prognostic biomarkers that predict the poor outcomes of diseases.Therefore,concomitant measurements of ALBI score and PHR or ALBI score and PLR will improve the predictive value that can differentiate hepatocellular carcinoma from non-malignant diseases.

关 键 词：Albumin-bilirubin score Hepatocellular carcinoma Non-malignant diseases Platelet-lymphocyte ratio Platelet-hemoglobin ratio 

分 类 号：R575[医药卫生—消化系统]